CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in October:

Jefferies Virtual Gene Therapy/Editing Summit Date: Thursday, October 1, 2020Time: 1:00 p.m. ET

Chardan Virtual 4th Annual Genetic Medicines ConferenceDate: Tuesday, October 6, 2020Time: 10:30 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503[email protected]

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167[email protected]

 

Source: CRISPR Therapeutics AG

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• NMDP Ranks Second in its Sixth Consecutive ‘Best Places to Work’ Recognition
• Voidtrace AI Unveils Cross-Chain Liquidity Intelligence Platform Ahead of $VOIDE Presale
• Craig Murphey of Purchase, George, & Murphey, P.C. Recognized in 2027 Edition of The Best Lawyers in America®